Patent ID: 9726673
Date: 2017-08-08
CPC Classifications: A61P,G01N

Claim:
1. A method for optimizing a B cell depletion therapy in a subject suffering from an immunological disorder comprising the steps of: (a) administering a therapeutically effective amount of a B cell depletion agent to the subject; (b) determining the serum BAFF level in a test sample from the subject at a first time point; (c) determining the serum BAFF level in a test sample from the subject at a second time point; (d) comparing the serum BAFF level in the test samples taken at the first and second time points, wherein an increase in the serum BAFF level from the first time point to the second time point is indicative of a decrease in the level of B cells and a decrease in the serum BAFF level from the first time point to the second time point is indicative of an increase in B cells levels in the subject; and (e) administering a therapeutically effective amount of the same B cell depletion agent or a different therapeutic agent to the subject whose serum BAFF levels are decreased from the first time point to the second time point, whereby said B cell depletion therapy is optimized wherein the B cell depletion agent is an anti-CD20 antibody or an anti-BR3 antibody.